• Yazan Zayed, Mahmoud Barbarawi, Babikir Kheiri, Momen Banifadel, Tarek Haykal, Adam Chahine, Laith Rashdan, Ahmed Aburahma, Ghassan Bachuwa, and Elfateh Seedahmed.
• Department of Internal Medicine, Hurley Medical Center, Michigan State University, Flint, MI, United States. Electronic address: yzayed1@hurleymc.com.
• J Crit Care. 2019 Apr 1; 50: 280-286.

PurposeDelirium commonly presents as a complication in critically ill patients. Our aim is to perform a meta-analysis investigating the role of haloperidol versus placebo in management (treatment and prophylaxis), of delirium in intensive care unit (ICU).Materials And MethodsOur study is a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing haloperidol versus placebo for treatment and/or prophylaxis of ICU-related delirium.ResultsSix RCTs representing 2552 patients. There was no significant difference between haloperidol and placebo-treated patients in short-term all-cause mortality (risk ratio [RR] 0.96; 95% confidence interval [CI] 0.81-1.14; P = 0.67), incidence of delirium (RR 0.93; 95% CI 0.65-1.34; P = 0.70), ICU length of stay (Mean difference [MD] 0.00 days; 95% CI -0.82-0.83; P = 0.99), or delirium/coma-free days (MD 0.09; 95% CI -0.05-0.24; P = 0.21). Haloperidol was not associated with increased risk for serious adverse events (RR 0.65; 95% CI 0.23-1.88; P = 0.43), QTc prolongation (RR 0.87; 95% CI 0.63-1.19; P = 0.38), or extrapyramidal symptoms (RR 0.84; 95% CI 0.57-1.23; P = 0.37).ConclusionAmong critically ill patients, haloperidol administration compared with placebo does not significantly affect short-term mortality, incidence of delirium, ICU length of stay, or delirium or coma-free days. Additionally, there was no increased risk of adverse events.Copyright © 2019 Elsevier Inc. All rights reserved.

16 keywords...

hide…